Baby Safety Alliance Expands Verification Program

3,200 products now Verified across 30+ categories-including new oversight for car seats and counterfeit prevention The Baby Safety Alliance is proud to announce the continued growth of its Verification Program, previously known as the JPMA Certification Program, making it even easier for parents to identify baby and children's products that have been independently tested and […]

E-fuels Market worth $66.25 billion by 2030 | MarketsandMarkets™

The globalE-fuels Marketis anticipated to grow from estimated USD 24.49 billion in 2025 to USD 66.25 billion by 2030, at a CAGR of 22.0% during the forecast period.The e-fuels market is driven by increasing demand for sustainable alternatives to fossil fuels in hard-to-decarbonize sectors like aviation, shipping, and heavy-duty transport. Rising global regulations on emissions,

Yum China Reports Second Quarter 2025 Results

Operating Profit Increased 14% YoY; OP Margin Expanded 100 Basis Points to 10.9%, a Second-Quarter Record High Same-Store Sales Growth Turned Positive, Driven by 10th Consecutive Quarter of Same-Store Transaction Growth Diluted EPS Up 5%, or 15% Excluding Mark-to-Market and F/X Impact Yum China Holdings, Inc. (the “Company” or “Yum China”) (NYSE: YUMC and HKEX:

Trailhead Biosystems Expands iPSC-Derived Portfolio with TrailBio® Hematopoietic Progenitor Cells

Trailhead Biosystems, Inc. (TrailBio.com), a biotechnology company advancing scalable human cell models derived from induced pluripotent stem cells (iPSCs), announces the commercial release ofTrailBio® Hematopoietic Progenitor Cells. These progenitor cells are derived from a single, well-characterizediPSC line using Trailhead's proprietary High-Dimensional Design-of-Experiments (HD-DoE®) platform, providing researchers with a consistent, scalable, and ready-to-use tool for hematopoietic

XPENG to Report Second Quarter 2025 Financial Results on Tuesday, August 19, 2025

XPENG to Report Second Quarter 2025 Financial Results on Tuesday, August 19, 2025 GlobeNewswire August 05, 2025 – Earnings Call Scheduled for 8:00 a.m. ET on August 19, 2025 – GUANGZHOU, China, Aug. 05, 2025 (GLOBE NEWSWIRE) — XPeng Inc. (“XPENG” or the “Company,” NYSE: XPEV and HKEX: 9868), a leading Chinese smart electric vehicle

GDS Announces Official Listing and Trading of its C-REIT on the Shanghai Stock Exchange from 8 August, 2025

GDS Announces Official Listing and Trading of its C-REIT on the Shanghai Stock Exchange from 8 August, 2025 GlobeNewswire August 05, 2025 SHANGHAI, China, Aug. 05, 2025 (GLOBE NEWSWIRE) — GDS Holdings Limited (“GDS Holdings”, “GDS” or the “Company”) (NASDAQ: GDS; HKEX: 9698), a leading developer and operator of high-performance data centers in China, today

Fortuna Advances Diamba Sud Gold Project in Senegal with Updated Mineral Resources; PEA Completion Targeted for Q4 2025

(TSX:FVI),(NYSE:FSM), VANCOUVER, British Columbia, Aug. 05, 2025 (GLOBE NEWSWIRE) — Fortuna Mining Corp. (NYSE: FSM | TSX: FVI) is pleased to report an updated Mineral Resource estimate as of July 7, 2025, for the Diamba Sud Gold Project located in Senegal. All dollar amounts in this news release are expressed in US dollars. Highlights of

Aicuris Presents Pharmacokinetic Data from the First-in-Human Clinical Trial of AIC468, a Novel Antisense Oligonucleotide Targeting BK Virus, at World Transplant Congress

Initial results from the First in Human (FIH) Phase 1 trial evaluating AIC468, a 2nd generation antisense oligonucleotide (ASO), in healthy volunteers demonstrated favorable pharmacokinetic (PK) characteristics AIC468 was safe and well tolerated in all evaluated patients to date Preclinical and human PK results suggest that efficacious kidney concentrations can be achieved by weekly or

Aicuris Presents Pharmacokinetic Data from the First-in-Human Clinical Trial of AIC468, a Novel Antisense Oligonucleotide Targeting BK Virus, at World Transplant Congress

Aicuris Presents Pharmacokinetic Data from the First-in-Human Clinical Trial of AIC468, a Novel Antisense Oligonucleotide Targeting BK Virus, at World Transplant Congress GlobeNewswire August 05, 2025 Initial results from the First in Human (FIH) Phase 1 trial evaluating AIC468, a 2nd generation antisense oligonucleotide (ASO), in healthy volunteers demonstrated favorable pharmacokinetic (PK) characteristics AIC468 was

Fortuna Advances Diamba Sud Gold Project in Senegal with Updated Mineral Resources; PEA Completion Targeted for Q4 2025

Fortuna Advances Diamba Sud Gold Project in Senegal with Updated Mineral Resources; PEA Completion Targeted for Q4 2025 GlobeNewswire August 05, 2025 VANCOUVER, British Columbia, Aug. 05, 2025 (GLOBE NEWSWIRE) — Fortuna Mining Corp. (NYSE: FSM | TSX: FVI) is pleased to report an updated Mineral Resource estimate as of July 7, 2025, for the

Scroll to Top